The interleukin (IL)-1β inhibitor canakinumab (Ilaris) showed promise for scuffling with the necessity for hip or knee substitute amongst patients with osteoarthritis in an exploratory…
The interleukin (IL)-1β inhibitor canakinumab (Ilaris) showed promise for scuffling with the necessity for hip or knee substitute amongst patients with osteoarthritis in an exploratory…